GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lunai Bioworks LNAI · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.17

-30.11%

Close of 29 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Lunai Bioworks

From its filings with the US Securities and Exchange Commission

SEC filings

Lunai Bioworks is based in Suite 906 Los Angeles, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker LNAI. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 June 2026, it reported revenue of $51,992 and a net loss of $3.6m. At that date it held total assets of $9.9m and shareholders' equity of −$9.0m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
18 Nov 2014
Employees
8
Head office
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES, CA, 90067
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. David WeinsteinChief Executive Officer, Director, since 2024$1.2m
  • Mr. Nathen FuentesChief Financial Officer$290,689
  • Mr. Douglas CalderIndependent Director$123,316
  • Mr. Mark CollinsIndependent Director$115,755
  • Mr. James McnultyIndependent Director$127,158
  • Mr. Chris TysonExecutive Vice President - Investor Relations, since 2024

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
28
Environment
26
Social
25
Governance
32
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Lunai Bioworks Inc focuses on colorectal cancer vaccines with MCV platform technology in clinical trials.
  • Enochian Biosciences develops MelCancerVac for cancer treatment in Denmark and Singapore trials.
  • The company has eight employees and operates in Health Care sector with biotechnology focus.

Weaknesses

  • Enochian Biosciences has only eight full-time employees in Los Angeles headquarters.
  • The company's Melvaccine is in pre-clinical stage in Denmark with limited development progress.
  • Tolerogenic dendritic cell (TDC) technology remains in pre-clinical stage in Denmark.

Opportunities

  • MelCancerVac (MCV) has phase I/II trials in Denmark and phase II in Singapore for cancer treatment.
  • Gene therapies for HIV/AIDS patients present new market opportunities in Health Care sector.
  • Clinical trials in Europe and Asia expand the company's global reach for vaccine development.

Threats

  • Melvaccine (MV) is in pre-clinical stage, delaying potential market entry.
  • TDC technology remains at pre-clinical stage, limiting near-term commercialization.
  • Limited employee count of eight may hinder rapid development and expansion.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.